Inhibitors of Tyrosine Kinases (TKI) and Small Interfering RNAs (siRNA) are Promising Targeted Cancer Treatments

Abstract

Background: In recent years, many investigators have focused on the development of drugs with the potential to influence the malignant phenotype. Clearly, our understanding of molecular and cellular processes behind such mechanisms has increased substantially through the past decades. This knowledge has led to an extensive search for targeted carcinoma treatment.

Significance of Dietary Antioxidants in Averting Cancer

“…Vitamin E, vitamin C (Ascorbic Acid) [42], β-carotene, vitamin E, flavonoids, minerals [43], vitamin D and vitamin K3 [44], Lutein, Lycopene, Selenium.…”

Epidemiology of Genetic Alterations in Progression of Breast Cancer

“…Transfection of BRCA1 N-terminal peptides that disrupted the cellular BRCA1-BARD1 interaction caused a loss of nuclear BRCA1 that correlated with increased apoptosis. Reducing the BARD1 levels by SiRNA caused small increase in apoptosis [63][64][65].…”

Organ Specific Cancers - Recent Advances in Diagnosis and Treatment

“…Recently a research conveys that inhibitors of Tyrosine Kinases (TKI) and Small Interfering RNAs (siRNA) are promising targeted cancer treatments [72]. Development of inhibitors of TKI and siRNA, with effects better than or at least similar to conventional therapy must be given high priority.…”

“…Only through such efforts may such treatment be fully developed and find its place in the treatment of malignant tumours, solely, as primary choice, or in combination with conventional cancer therapy. RNA interference is likely to become a treatment option for some cancers, either alone or as a supplement to traditional treatment [72].…”